Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1967 1
1968 2
1973 1
1975 7
1976 3
1977 4
1978 6
1979 4
1980 3
1981 3
1982 1
1983 10
1984 11
1985 10
1986 19
1987 13
1988 11
1989 12
1990 16
1991 18
1992 25
1993 18
1994 32
1995 28
1996 29
1997 37
1998 48
1999 39
2000 50
2001 42
2002 55
2003 85
2004 79
2005 86
2006 106
2007 132
2008 165
2009 140
2010 143
2011 140
2012 177
2013 223
2014 176
2015 216
2016 207
2017 238
2018 258
2019 215
2020 232
2021 274
2022 234
2023 236
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

3,738 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Schizophrenia 18"
Page 1
Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016.
Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Charlson FJ, et al. Schizophr Bull. 2018 Oct 17;44(6):1195-1203. doi: 10.1093/schbul/sby058. Schizophr Bull. 2018. PMID: 29762765 Free PMC article. Review.
Globally, prevalent cases rose from 13.1 (95% UI: 11.6-14.8) million in 1990 to 20.9 (95% UI: 18.5-23.4) million cases in 2016. Schizophrenia contributes 13.4 (95% UI: 9.9-16.7) million years of life lived with disability to burden of disease globally. CONCLUSION: A …
Globally, prevalent cases rose from 13.1 (95% UI: 11.6-14.8) million in 1990 to 20.9 (95% UI: 18.5-23.4) million cases in 2016. Sc …
Cigarette smoking and schizophrenia: Mendelian randomisation study.
Chen J, Chen R, Xiang S, Li N, Gao C, Wu C, Zhang Q, Zhao Y, Liao Y, Stewart R, Xu Y, Shi Y, Li Z. Chen J, et al. Br J Psychiatry. 2021 Feb;218(2):98-103. doi: 10.1192/bjp.2020.116. Br J Psychiatry. 2021. PMID: 32552923
BACKGROUND: The link between schizophrenia and cigarette smoking has been well established through observational studies. ...CONCLUSIONS: Cigarette smoking is a complex behaviour in people with schizophrenia. Understanding factors underlying the observed …
BACKGROUND: The link between schizophrenia and cigarette smoking has been well established through observational studies. ...C …
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.
Guo LK, Su Y, Zhang YY, Yu H, Lu Z, Li WQ, Yang YF, Xiao X, Yan H, Lu TL, Li J, Liao YD, Kang ZW, Wang LF, Li Y, Li M, Liu B, Huang HL, Lv LX, Yao Y, Tan YL, Breen G, Everall I, Wang HX, Huang Z, Zhang D, Yue WH. Guo LK, et al. Mil Med Res. 2023 Jun 2;10(1):24. doi: 10.1186/s40779-023-00459-7. Mil Med Res. 2023. PMID: 37269009 Free PMC article.
BACKGROUND: Choosing the appropriate antipsychotic drug (APD) treatment for patients with schizophrenia (SCZ) can be challenging, as the treatment response to APD is highly variable and difficult to predict due to the lack of effective biomarkers. ...The genetic and …
BACKGROUND: Choosing the appropriate antipsychotic drug (APD) treatment for patients with schizophrenia (SCZ) can be challenging, as …
Theranostic Biomarkers for Schizophrenia.
Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Perkovic MN, et al. Int J Mol Sci. 2017 Mar 30;18(4):733. doi: 10.3390/ijms18040733. Int J Mol Sci. 2017. PMID: 28358316 Free PMC article. Review.
However, there are still no validated and reliable biomarkers in clinical use for schizophrenia. This review will address potential biomarkers in schizophrenia. ...Therefore, the development of the diagnostic, prognostic and theranostic biomarkers is an urgent and a …
However, there are still no validated and reliable biomarkers in clinical use for schizophrenia. This review will address potential b …
Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia: A Randomized Clinical Trial.
Kang Z, Qin Y, Sun Y, Lu Z, Sun Y, Chen H, Feng X, Zhang Y, Guo H, Yan H, Yue W. Kang Z, et al. JAMA Netw Open. 2023 Oct 2;6(10):e2335518. doi: 10.1001/jamanetworkopen.2023.35518. JAMA Netw Open. 2023. PMID: 37801319 Free PMC article. Clinical Trial.
IMPORTANCE: Limited evidence supports multigenetic pharmacogenomics-guided treatment (MPGT) in schizophrenia. OBJECTIVE: To evaluate the clinical effectiveness of MPGT in schizophrenia in a randomized clinical trial (RCT). DESIGN, SETTING, AND PARTICIPANTS: This RCT …
IMPORTANCE: Limited evidence supports multigenetic pharmacogenomics-guided treatment (MPGT) in schizophrenia. OBJECTIVE: To evaluate …
Saccadic suppression in schizophrenia.
Lencer R, Meyhöfer I, Triebsch J, Rolfes K, Lappe M, Watson T. Lencer R, et al. Sci Rep. 2021 Jun 23;11(1):13133. doi: 10.1038/s41598-021-92531-2. Sci Rep. 2021. PMID: 34162939 Free PMC article.
About 40% of schizophrenia patients report discrete visual disturbances which could occur if saccadic suppression, the decrease of visual sensitivity around saccade onset, is impaired. Two mechanisms contribute to saccadic suppression: efference copy processing and backwar …
About 40% of schizophrenia patients report discrete visual disturbances which could occur if saccadic suppression, the decrease of vi …
Gut permeability and its clinical relevance in schizophrenia.
Ishida I, Ogura J, Aizawa E, Ota M, Hidese S, Yomogida Y, Matsuo J, Yoshida S, Kunugi H. Ishida I, et al. Neuropsychopharmacol Rep. 2022 Mar;42(1):70-76. doi: 10.1002/npr2.12227. Epub 2022 Jan 25. Neuropsychopharmacol Rep. 2022. PMID: 35080340 Free PMC article.
AIM: We aimed to examine the gut permeability in patients with schizophrenia and its relevance to schizophrenia symptoms, medication, cognitive functions, and blood immune markers. ...In addition, the LMR was negatively correlated with the total Z-score of th …
AIM: We aimed to examine the gut permeability in patients with schizophrenia and its relevance to schizophrenia symptoms, medi …
Cannabis Cessation, Inflammatory Markers and Schizophrenia.
Romeo B, Lestra V, Martelli C, Benyamina A, Hamdani N. Romeo B, et al. J Dual Diagn. 2022 Jan-Mar;18(1):33-41. doi: 10.1080/15504263.2021.2013697. Epub 2022 Jan 5. J Dual Diagn. 2022. PMID: 34985404
Objective A dysbalance of the immune system in schizophrenia has been largely described but few studies have investigated the impact of cannabis use on inflammatory markers in patients with schizophrenia. ...Results: After four weeks of cannabis cessation (as confir …
Objective A dysbalance of the immune system in schizophrenia has been largely described but few studies have investigated the impact …
Early motor developmental milestones and schizophrenia: A systematic review and meta-analysis.
Filatova S, Koivumaa-Honkanen H, Hirvonen N, Freeman A, Ivandic I, Hurtig T, Khandaker GM, Jones PB, Moilanen K, Miettunen J. Filatova S, et al. Schizophr Res. 2017 Oct;188:13-20. doi: 10.1016/j.schres.2017.01.029. Epub 2017 Jan 26. Schizophr Res. 2017. PMID: 28131598 Free article. Review.
Early motor developmental milestones, such as learning to walk, are predictors of later schizophrenia but studies have not been systematically reviewed. ...The following motor milestones were significantly associated with adult schizophrenia risk: walking uns …
Early motor developmental milestones, such as learning to walk, are predictors of later schizophrenia but studies have not bee …
Early and very early-onset schizophrenia compared with adult-onset schizophrenia: French FACE-SZ database.
Coulon N, Godin O, Bulzacka E, Dubertret C, Mallet J, Fond G, Brunel L, Andrianarisoa M, Anderson G, Chereau I, Denizot H, Rey R, Dorey JM, Lançon C, Faget C, Roux P, Passerieux C, Dubreucq J, Leignier S, Capdevielle D, André M, Aouizerate B, Misdrahi D, Berna F, Vidailhet P, Leboyer M, Schürhoff F. Coulon N, et al. Brain Behav. 2020 Feb;10(2):e01495. doi: 10.1002/brb3.1495. Epub 2020 Jan 7. Brain Behav. 2020. PMID: 31908151 Free PMC article.
OBJECTIVE: To compare the clinical symptomatology in patients with Early-Onset Schizophrenia (EOS, N = 176), especially the subgroup Very Early Onset Schizophrenia (VEOS) and Adult Onset Schizophrenia (AOS, N = 551). METHOD: In a large French multicentric sam …
OBJECTIVE: To compare the clinical symptomatology in patients with Early-Onset Schizophrenia (EOS, N = 176), especially the subgroup …
3,738 results